Here are the 10-K annual reports from Heartbeam, Inc. Warrant (BEATW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BEATW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEATW filings page.
HeartBeam, Inc. is a development-stage medical technology company focused on portable, cable‑free 12‑lead ECG systems for ambulatory cardiac monitoring. Its HeartBeam System, a credit card–sized 3D ECG device with cloud software and physician portal, received FDA clearance for arrhythmia assessment in December 2024 and for 12‑lead synthesis software in December 2025.
The company generated no revenue in 2025 and had 16 employees as of December 31, 2025, growing to 17 in early 2026 with the hire of a Chief Commercial Officer to lead commercialization. Management and the auditor highlight substantial doubt about HeartBeam’s ability to continue as a going concern, citing limited working capital and the need for additional financing, which may be dilutive.
HeartBeam plans a limited U.S. launch in early 2026 targeting concierge and preventive cardiology practices, while pursuing expanded indications such as heart attack detection, an extended‑wear 12‑lead patch, and AI‑based diagnostic algorithms. The company operates in a large, growing cardiac monitoring market and reports a broad patent portfolio, including 25 issued patents worldwide and multiple pending applications protecting its 3D ECG, patch, smartwatch and AI technologies.